Molecular Formula | C13H10ClN3O |
Molar Mass | 259.69 |
Density | 1.46 g/cm3 |
Melting Point | 256 °C(dec.) |
Boling Point | 501.6 °C at 760 mmHg |
Flash Point | 257.1 °C |
Appearance | Slightly yellowish to reddish yellow crystals or powder |
Storage Condition | 2-8℃ |
MDL | MFCD00870704 |
In vitro study | Ro5-3335 has antiproliferative activity against human CBF leukemia cell lines, with IC 50 s of 1.1 μM, 21.7 μM and 17.3 μM for ME-1, Kasumi-1 and REH, respectively. Ro5-3335 inhibits definitive hematopoiesis in zebrafish embryos. Ro5-3335 does not completely break apart RUNX1-CBFβ interaction, but changes the conformation of their complex or increases the distance between RUNX1 and CBFβ in the complex. |
In vivo study | Ro5-3335 is identified as an inhibitor of RUNX1–CBFβ function in zebrafish models. Ro5-3335 rescues preleukemic phenotype in a RUNX1-ETO transgenic zebrafish. Ro5-3335 (300 mg/kg/d; p.o; for 30 days) reduces leukemia burden in a mouse CBFB-MYH11 leukemia model. Animal Model: C57BL/6 mice (leukemic model) Dosage: 300 mg/kg Administration: Oral administration; daily; for 30 days Result: Reduced the number of c-kit + cells in the transplanted mice and leukemic cell infiltration in the livers, bone marrow and spleen. |